Anti-IL36RN therapeutic antibody (Pre-made Spesolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Spesolimab (BI 655130) is a humanised monoclonal antibody being developed by Boehringer Ingelheim, for the treatment of generalised pustular psoriasis, Crohn's disease, palmoplantar pustulosis, ulcerative colitis and atopic dermatitis.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-532-1mg	1mg	3090
GMP-Bios-ab-532-10mg	10mg	21890
GMP-Bios-ab-532-100mg	100mg	148000
GMP-Bios-ab-532-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-IL36RN therapeutic antibody (Pre-made Spesolimab biosimilar,Whole mAb)
INN Name	Spesolimab
Target	IL36RN
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	6u6u:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	na
Conditions Approved	na
Conditions Active	Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis
Conditions Discontinued	na
Development Tech	na